期刊
ATHEROSCLEROSIS
卷 251, 期 -, 页码 263-265出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2016.07.008
关键词
LAL deficiency; LIPA; Familial hypercholesterolemia; Cholesteryl ester storage disease
资金
- Vidi from the Netherlands Organisation for Scientific Research (NWO) [016.156.445]
- CardioVascular Research Initiative [CVON2011-19]
- European Union [TransCard: FP7-603091-2]
- Synageva BioPharma
Background and aims: We recently identified lysosomal acid lipase (LAL) deficiency, a recessive disease caused by mutations in LIPA, in 3 patients with a clinical diagnosis of familial hypercholesterolemia (FH). We aimed to determine the prevalence of LIPA mutations among individuals with a clinical FH diagnosis. Methods: In 276 patients with phenotypic FH, in whom no genetic basis for their phenotype was found, LIPA was sequenced. All variants were assessed for pathogenicity using a literature search and in silico prediction models. Results: We included 213 adults and 63 children with mean (+/- SD) LDL-C levels of 7.8 +/- 1.3 and 4.4 +/- 1.5 mmol/L, respectively. Twenty-one variants were identified. Six patients were heterozygous carrier of a (potentially) pathogenic mutation. No homozygous LIPA mutation carriers were identified. Conclusions: Our data show that LAL deficiency was not missed as diagnosis in our study population but the frequency of heterozygous LIPA mutations implies that the FH population might be relatively enriched with LIPA mutation carriers. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据